The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer's disease and mild cognitive impairment

Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

Volumn 1, Issue 3, 2015, Pages 295-302

  Klavins, Kristaps ^a   Koal, Therese ^a   Dallmann, Guido ^a   Marksteiner, Josef ^b   Kemmler, Georg ^c   Humpel, Christian ^c  

^a BIOCRATES LIFE SCIENCES AG   (Austria)

^b State Psychiatric Hospital   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Alzheimer's disease; Diagnosis; Metabolomics; Mild cognitive impairment; Plasma

Indexed keywords

EID: 84939156383     PISSN: None     EISSN: 23528729     Source Type: Journal    
DOI: 10.1016/j.dadm.2015.05.003     Document Type: Article

References (41)

1. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002, 297:353-356. Review. Science 2002;297(5590):2209.
2. Morris G.P., Clark I.A., Vissel B. Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease. Acta Neuropathol Commun 2014, 2:135.
3. Nisbet R.M., Polanco J.C., Ittner L.M., Götz J. Tau aggregation and its interplay with amyloid-β. Acta Neuropathol 2015, 129:207-220.
4. Humpel C., Marksteiner J. Cerebrovascular damage as a cause for Alzheimer's disease?. Curr Neurovasc Res 2005, 2:341-347.
5. Erickson M.A., Banks W.A. Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease. J Cereb Blood Flow Metab 2013, 33:1500-1513.
6. Blennow K. CSF biomarkers for mild cognitive impairment. J Intern Med 2005, 256:224-234.
7. Humpel C. Identifying and validating biomarkers for diagnosing Alzheimer's disease. Trends Biotechnol 2011, 29:26-32.
8. Ray S., Britschgi M., Herbert C., Takeda-Uchimura Y., Boxer A., Blennow K., et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 2007, 13:1359-1362.
9. Marksteiner J., Kemmler G., Weiss E.M., Knaus G., Ullrich C., Mechtcheriakov S., et al. Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 2009, 32:539-540.
10. Björkqvist M., Ohlsson M., Minthon L., Hansson O. Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease. PLoS One 2012, 7:e29868.
11. Mapstone M., Cheema A.K., Fiandaca M.S., Zhong X., Mhyre T.R., MacArthur L.H., et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med 2014, 20:415-418.
12. Perry G., Nunomura A., Raina A.K., Aliev G., Siedlak S.L., Harris P.L., et al. A metabolic basis for Alzheimer disease. Neurochem Res 2003, 28:1549-1552.
13. Ahmad W. Overlapped metabolic and therapeutic links between Alzheimer and diabetes. Mol Neurobiol 2013, 47:399-424.
14. Wood P.L. Mass spectrometry strategies for clinical metabolomics and lipidomics in psychiatry, neurology, and neuro-oncology. Neuropsychopharmacology 2014, 39:24-33.
15. Proitsi P., Kim M., Whiley L., Pritchard M., Leung R., Soininen H., et al. Plasma lipidomics analysis finds long chain cholesteryl esters to be associated with Alzheimer's disease. Transl Psychiatry 2015, 5:e494.
16. Olazaran J., Gil-deGomez L., Rodriguez-Martin A., Valenti-Soler M., Frades-Payo B., Marin-Munoz J., et al. A blood-based, 7-metabolite signature for the early diagnosis of Alzheimer's disease. J Alzheimers Dis 2015, 45:1157-1173.
17. Marksteiner J., Imarhiagbe D., Defrancesco M., Deisenhammer E.A., Kemmler G., Humpel C. Analysis of 27 vascular-related proteins reveals that NT-proBNP is a potential biomarker for Alzheimer's disease and mild cognitive impairment: A pilot-study. Exp Gerontol 2014, 50:114-121.
18. Koal T., Klavins K., Seppi D., Kemmler G., Humpel C. Sphingomyelin SM(d18:1/18:0) is significantly enhanced in cerebrospinal fluid samples dichotomized by pathological β-amyloid, tau and phospho-tau-181 levels. J Alzheimers Dis 2014, 44:1193-1201.
19. Razali N.M., Wa Y.B. Power comparison of Shapiro-Wilk, Kolmogorov-Smirnov, Lilliefors and Anderson-Darling tests. J Stat Modeling Analytics 2011, 2:21-33.
20. Levin J.R., Serlin R.C., Seaman M.A. A controlled, powerful multiple-comparison strategy for several situations. Psychol Bull 1994, 115:153-159.
21. Arlot S. A survey of cross-validation procedures for model selection. Statist Surv 2010, 4:40-79.
22. Caraguel C.G.B., Vanderstichel R. The two-step Fagan's nomogram: Ad hoc interpretation of a diagnostic test result without calculation. Evid Based Med 2013, 18:125-128.
23. Orešič M., Hyötyläinen T., Herukka S.K., Sysi-Aho M., Mattila I., Seppänan-Laakso T., et al. Metabolome in progression to Alzheimer's disease. Transl Psychiatry 2011, 1:1-9.
24. Whiley L., Sen A., Heaton J., Proitsi P., Garci-Gomez D., Leung R., et al. Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease. Neurobiol Aging 2014, 35:271-278.
25. González-Domínguez R., García-Barrera T., Gómez-Ariza J.L. Combination of metabolomic and phospholipid-profiling approaches for the study of Alzheimer's disease. J Proteomics 2014, 104:37-47.
26. Grimm M., Grösgen S., Riemenschneider M., Tanila H., Grimm H.S., Hartmann T. From brain to food: Analysis of phosphatidylcholines, lyso-phosphatidylcholins and phosphatidylcholin-plasmalogens derivates in Alzheimer's disease human post mortem brains and mice model via mass spectrometry. J Chromatogr A 2011, 1218:7713-7722.
27. Tajima Y., Ishikawa M., Maekawa K., Murayama M., Senoo Y., Nishimaki-Mogami T., et al. Lipidomics analysis of brain tissues and plasma in a mouse model expressing mutated human amyloid precursor protein/tau for Alzheimer's disease. Lipids Health Dis 2013, 12:68.
28. Hicks J.B., Lai Y., Sheng W., Yang X., Zhu D., Sun G.Y., et al. Amyloid-bet peptide induces temporal membrane biphasic changes in astrocytes through cytosolic phospholipase A2. Biochim Biophys Acta 2008, 1778:2512-2519.
29. Lee J.C.-M., Simonyi A., Sun A.Y., Sun G.Y. Phospholipases A2 and neural membrane dynamics: Implications for Alzheimer's disease. J Neurochem 2011, 116:813-819.
30. Li N.J., Liu W.T., Li W., Li S.Q., Chen X.H., Bi K.S., et al. Plasma metabolic profiling of Alzheimer's disease by liquid chromatography/mass spectrometry. Clin Biochem 2010, 43:993-997.
31. Mulder C., Wahlund L.O., Teerlink T., Blomberg M., Veerhuis R., Van Kamp G.J., et al. Decreased lysophosphatidylcholine/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer's disease. J Neural Transm 2003, 110:949-955.
32. Frisaldi V., Panza F., Seripa D., Farooqui T., Faroogui A.A. Glycerophospholipids and glycerophospholipid-derived lipid mediators: A complex meshwork in Alzheimer's disease pathology. Prog Lipid Res 2011, 50:313-330.
33. Cunningham T.J., Yao L., Lucena A. Product inhibition of secreted phospholipase A2 may explain lysophosphatidylcholines' unexpected therapeutic properties. J Inflamm (Lond) 2008, 5:17.
34. Yu Z., Zhai G., Singmann P., He Y., Xu T., Prehn C., et al. Human serum metabolic profiles are age dependent. Aging Cells 2012, 11:960-967.
35. Gonzalez-Covarrubias V., Dane A., Hankemeier T., Vreeken R.J. The influence of citrate, EDTA, and heparin anticoagulants to human plasma LC-MS lipidomics profiling. Metabolomics 2013, 9:337-348.
36. Yu Z., Kastenmüller G., He Y., Belcredi P., Möller G., Prehn C., et al. Differences between human plasma and serum metabolite profiles. PLoS One 2011, 6:e21230.
37. Breier M., Wahl S., Prehn C., Fugmann M., Ferrari U., Weise M., et al. Targeted metabolomics identifies reliable and stable metabolites in human serum and plasma samples. PLoS One 2014, 9:e89728.
38. Mathew S., Krug S., Skurk T., Halama A., Stank A., Artati A., et al. Metabolomics of Ramadan fasting: An opportunity for the controlled study of physiological response to food intake. J Trans Med 2014, 12:161.
39. Kamlage B., Maldonado S.G., Bethan B., Peter E., Schmitz O., Liebenberg V., et al. Quality markers addressing preanalytical variations of blood and plasma processing identified by broad and targeted metabolomics profiling. Clin Chem 2014, 60:399-412.
40. Pinto J., Domingues M.R.M., Galhano E., Pita C., do Ceu Almeida M., Carreira I.M., et al. Human plasma stability during handling and storage: Impact on NMR metabolomics. Analyst 2014, 139:1168-1177.
41. O'Bryant S.E., Gupta V., Henriksen K., Edwards M., Jeromin A., Lista S., et al. Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. Alzheimers Dement 2015, 11:549-560. STAR-B and BBBIG working groups.